GlassScriptPhysician profile
Francine Fane Foo
NPI 1164086229
$4,070.39
in general payments reported to CMS, 2019-2025
33 companies · $2,620 in 2025
The $2,620 reported for 2025 was more than what 81% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $29.36 · 2023: $663 · 2024: $758 · 2025: $2,620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,041.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,041.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $506.92 | 2024-2025 | Freestyle Libre 3, Freestyle Libre, Proclaim |
| Corcept Therapeutics | $370.92 | 2024-2025 | Korlym |
| Novo Nordisk INC | $339.42 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Embecta Corp. | $310.21 | 2023-2024 | Bd Nano 2nd Gen Pen Needle |
| Insulet Corporation | $262.98 | 2025 | Omnipod, Omnipod |
| Xeris Pharmaceuticals, INC. | $241.21 | 2025 | Gvoke Hypopen, Recorlev |
| Boehringer Ingelheim Pharmaceuticals, INC. | $224.73 | 2022-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $222.05 | 2023-2025 | |
| Mannkind Corporation | $186.02 | 2023-2025 | Afrezza |
| Lilly USA, LLC | $180.42 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Medtronic, INC. | $168.82 | 2023-2025 | Minimed 780g |
| Recordati_rare_diseases_inc. | $131.41 | 2023-2025 | Isturisa, Signifor Lar |
| Radius Health, INC. | $113.80 | 2023-2025 | |
| Madrigal Pharmaceuticals | $88.98 | 2025 | Rezdiffra |
| Abbvie INC. | $82.26 | 2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $70.32 | 2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $63.24 | 2024-2025 | |
| Amgen INC. | $54.61 | 2025 | Tepezza, Evenity |
| Alexion Pharmaceuticals, INC. | $53.52 | 2024-2025 | Strensiq |
| Chiesi USA, INC. | $53.37 | 2025 | Mycapssa |
| Ascendis Pharma Endocrinology INC | $52.22 | 2025 | Yorvipath |
| Ionis Pharmaceuticals, INC. | $36.21 | 2025 | Tryngolza |
| Tolmar, INC. | $33.19 | 2024 | |
| Almatica Pharma LLC | $32.37 | 2024 | Teriparatide |
| Merck Sharp & Dohme LLC | $28.82 | 2023-2025 | Pifeltro, Delstrigo, Dificid |
| Sequel Med Tech, LLC | $27.27 | 2025 | Twiist |
| Cequr Corporation | $24.35 | 2025 | Cequr Simplicity |
| Dynavax Technologies Corporation | $18.89 | 2025 | Heplisav-B |
| Astrazeneca Pharmaceuticals LP | $18.39 | 2023 | Farxiga |
| Ibsa Pharma INC. | $17.62 | 2024 | Tirosint, Licart |
| Neurocrine Biosciences, INC. | $16.27 | 2025 | |
| Janssen Pharmaceuticals, INC | $14.09 | 2024 | Xarelto |
| Ucb, INC. | $12.93 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francine Foo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.